沙特阿拉伯基于振动控制瞬时弹性成像的代谢功能障碍相关脂肪性肝病患病率:一项前瞻性队列研究
该研究基于沙特阿拉伯7个初级保健中心的前瞻性人群队列GENESIS,采用振动控制瞬时弹性成像评估成人代谢功能障碍相关脂肪性肝病(MASLD)及肝纤维化。结果显示,MASLD粗患病率为37.3%(95%CI 35.6%-39.0%),年龄和性别调整后为34.2%(95%CI 32.5%-35.9%);合并MASLD者中4.3%存在显著纤维化。糖尿病、腰围和阻塞性睡眠呼吸暂停高风险与MASLD独立相关;糖尿病、男性和腰围与显著纤维化独立相关。
要点
- 沙特成人MASLD粗患病率37.3%,年龄性别调整后34.2%。
- MASLD患者中显著纤维化比例为4.3%。
- 糖尿病、腰围和OSA高风险与MASLD独立相关。
核心结论
- MASLD影响超过三分之一的沙特成人,与中心性肥胖和代谢功能障碍相关,而显著纤维化相对较低。
- 这些发现提供了沙特阿拉伯首个国家层面前瞻性人群水平的MASLD估计,并支持可扩展的基于振动控制瞬时弹性成像的风险分层。
研究设计与样本
- 研究为前瞻性、人群为基础的GENESIS队列的横断面分析,覆盖沙特阿拉伯7个初级保健中心,时间范围为2024年3月至2025年6月。
- 纳入符合条件的成人,进行临床评估、实验室检测和振动控制瞬时弹性成像。
- MASLD定义为受控衰减参数≥268 dB/m且至少1项心血管代谢危险因素;显著纤维化定义为肝硬度测量≥8 kPa。
- 分析队列共2979名参与者,平均年龄41.9岁,49.7%为男性。
主要发现
- 1111名参与者符合MASLD标准,粗患病率为37.3%(95%CI 35.6%-39.0%),年龄和性别调整后患病率为34.2%(95%CI 32.5%-35.9%)。
- 糖尿病(OR 1.80,95%CI 1.43-2.27)、腰围(OR 1.35,95%CI 1.30-1.40)和高阻塞性睡眠呼吸暂停风险(OR 1.47,95%CI 1.21-1.80)与MASLD独立相关。
- 在MASLD个体中,糖尿病(OR 4.41,95%CI 2.12-9.14)、男性(OR 2.83,95%CI 1.31-6.13)和腰围(OR 1.24,95%CI 1.11-1.39)与显著纤维化独立相关。
关键数值与推荐
- MASLD诊断标准:受控衰减参数≥268 dB/m且至少1项心血管代谢危险因素。
- 显著纤维化标准:肝硬度测量≥8 kPa。
- MASLD粗患病率37.3%(95%CI 35.6%-39.0%),年龄和性别调整后34.2%(95%CI 32.5%-35.9%)。
- MASLD患者中显著纤维化比例4.3%。
临床怎么用
- 在初级保健中,可考虑使用振动控制瞬时弹性成像对成人进行MASLD及纤维化风险分层。
- 对于中心性肥胖、糖尿病或高阻塞性睡眠呼吸暂停风险的个体,应关注MASLD筛查。
- MASLD患者中,男性、糖尿病和腰围增加提示显著纤维化风险较高,需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease is the most common chronic liver disease worldwide. We aimed to estimate the prevalence, severity, and metabolic determinants of metabolic dysfunction-associated steatotic liver disease and liver fibrosis among Saudi adults using vibration-controlled transient elastography. METHODS: We conducted a cross-sectional analysis from the prospective, population-based Genomics and Environmental Noninvasive Evaluation for Saudi Intrahepatic Steatosis (GENESIS) cohort across 7 primary care centers in Saudi Arabia between March 2024 and June 2025. Eligible adults underwent clinical assessment, laboratory testing, and vibration-controlled transient elastography. We defined metabolic dysfunction-associated steatotic liver disease as controlled attenuation parameter ≥268 dB/m with ≥1 cardiometabolic risk factor, and significant fibrosis as liver stiffness measurement ≥8 kPa. RESULTS: Among 2979 participants included in the analytic cohort (mean age, 41.9 years; 49.7% men), 1111 met metabolic dysfunction-associated steatotic liver disease criteria, yielding a crude prevalence of 37.3% (95% confidence interval, 35.6%-39.0%) and an age- and sex-adjusted prevalence of 34.2% (95% confidence interval, 32.5%-35.9%). Forty-eight (4.3%) participants with metabolic dysfunction-associated steatotic liver disease had significant fibrosis. Diabetes (odds ratio, 1.80; 95% confidence interval, 1.43-2.27), waist circumference (odds ratio, 1.35; 95% confidence interval, 1.30-1.40), and high obstructive sleep apnea risk (odds ratio, 1.47; 95% confidence interval, 1.21-1.80) were independently associated with metabolic dysfunction-associated steatotic liver disease. Diabetes (odds ratio, 4.41; 95% confidence interval, 2.12-9.14), male sex (odds ratio, 2.83; 95% confidence interval, 1.31-6.13), and waist circumference (odds ratio, 1.24; 95% confidence interval, 1.11-1.39) were independently associated with significant fibrosis among individuals with metabolic dysfunction-associated steatotic liver disease. CONCLUSIONS: Metabolic dysfunction-associated steatotic liver disease affects more than one-third of Saudi adults and is associated with central obesity and metabolic dysfunction, whereas significant fibrosis remains relatively low. These findings provide the first prospective, population-level metabolic dysfunction-associated steatotic liver disease estimates at a country level in Saudi Arabia and support scalable vibration-controlled transient elastography-based risk stratification.
引用
- Alqahtani SA, AlMuhaidib S, Sanai FM, et al. Vibration-Controlled Transient Elastography-Based Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Saudi Arabia: A Prospective Cohort Study. Clin Gastroenterol Hepatol. 2026. PMID: 42456913. doi:10.1016/j.cgh.2026.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。